Simplify Logo
BeOne

BeOne

Global oncology therapeutics discovery, development, manufacturing

Associate Director - Digital Clinical Operations

Full-Time
$143.3k - $193.3k/yr

+ Annual bonus plan + Discretionary equity awards + Employee Stock Purchase Plan

Senior, Expert
Bachelor's, Master's
Remote in USA
Remote

Travel is required as needed.

About the job

Requirements
  • Bachelor’s or master’s degree in computer science or a related degree.
  • At least 8 years of experience in drug development clinical trial operations.
  • Clinical Operations domain expertise.
  • Experience with business analysis on technology projects.
  • Experience with core clinical systems.
  • Experience with the software development life cycle.
  • Experience with validated systems.
  • Familiarity with clinical operations applications such as Clinical Trial Management Systems.
  • Requirement gathering and documentation skills.
  • Process modeling skills.
  • Ability to work collaboratively with functional leadership and external partners to forge partnerships and manage expectations.
  • Strong cross-cultural awareness and strong verbal and written communication skills to convey complex insights to non-technical stakeholders.
  • Ability to collaborate with cross-functional clinical teams to understand business needs and deliver outcome-aligned solutions.
  • Conceptual, analytical, problem-solving, and troubleshooting skills.
  • Ability to drive forward progress.
Responsibilities
  • Detail enhancements for existing Clinical Trial Management Systems and other digital solutions used by Global Clinical Operations teams in planning, study start-up, clinical trial management, and study closeout, ensuring data are fit for intended decision-making.
  • Engage clinical stakeholders across geographies and functions to represent the clinical teams’ needs in the delivery of Clinical Trial Management System enhancements.
  • Elicit clear requirements from stakeholders and ensure organizational, regional, and process alignment, including process standardization, optimization, and automation.
  • Facilitate demand prioritization through objective value assessments, align priorities with organizational priorities, communicate priorities to stakeholders, translate priorities into plans with the development team, and manage stakeholder expectations.
  • Draft and finalize business requirements for prioritized enhancements.
  • Coordinate with Development and Information Technology teams to refine and finalize user stories for functional requirements, participate in sprint planning and sprint testing, and participate in software development life cycle testing, including user acceptance testing.
  • Ensure Clinical Trial Management Systems and other digital applications align with Global Clinical Operations processes; define process flows where needed and identify process optimization or process solutions that complement digital solutions.
  • Support the strategic evolution of Clinical Trial Management Systems and other digital solutions through near-term and long-term roadmaps.
  • Define and articulate the value proposition of requests using quantifiable and qualitative measures.
  • Define, track, and share business outcome value measures for digital investments.
  • Represent Global Clinical Operations business interests as a key member of the implementation team.
  • Review proposed designs to ensure solutions meet the actual need and expected value.
  • Curate the demand backlog and keep user stories and priorities up to date.
  • Manage the network of champions and foster two-way communication between end users and the product team.
  • Set up and maintain a SharePoint website for communication with end users and champions.
  • Bring innovative approaches and emerging industry technology into the organization.
  • Work with Global Clinical Operations clinical stakeholders and Development and Information Technology organizations to support implementation of novel technology solutions, processes, and roles and responsibilities.
  • Forge relationships with users to understand requirements and processes, identify automation opportunities, and collaborate with development and vendor teams to create fit-for-purpose solutions.
  • Analyze technology and industry trends to identify opportunities for cost-effective, innovative, cohesive, efficient, reliable, and compliant clinical trial and operations solutions.
  • Implement the Global Clinical Operations technology roadmap to increase productivity and reduce clinical trial costs and inefficiencies.
  • Monitor, evaluate, and optimize the performance and quality of technology solutions, and troubleshoot and resolve issues.
  • Manage project progress, timelines, accountabilities, risks, and costs.
  • Promote agility, compliance, process orientation, data-driven decision-making, and thoughtful use of technology and innovation.
  • Partner with Development Data Science, Quality Assurance, and Information Technology departments to support documentation for computerized systems, including lifecycle management and implementation of innovative systems.
  • Develop solution requirements and standards with Clinical Operations, Data Management, Supply Chain, and other stakeholders.
  • Identify pain points and manual workflows and develop technological solutions using existing and innovative approaches.
  • Take accountability for business value realization of technology solutions and plan and deliver change tactics, including communications, training, user communities, and adoption drives.
  • Prioritize system usability, user needs, user expectations, and user satisfaction while reducing user burden.
  • Oversee consultants or analysts on a matrixed team as needed.
Desired Qualifications
  • Familiarity with data processing or data engineering.

About the company

BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dongcheng District, China

Founded

2010

Get referred to BeOne

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 25, 2026 FDA approval expanded TEVIMBRA in first-line HER2-positive gastroesophageal cancer.
  • August 31, 2026 Phase 3 survival data strengthened ZIIHERA-containing regimens.
  • Q2 2026 revenue hit $1.7 billion; management raised 2026 guidance to $6.8 billion.

What critics are saying

  • BeOne accepted developed-market pricing parity and Medicaid rebates on future U.S. approvals.
  • Zydus' BRUKINSA ANDA lawsuit targets patents; a 2034 composition patent remains the fortress.
  • AbbVie's trade-secrets case over BGB-16673 still threatens the BTK-degrader franchise.

What makes BeOne unique

  • BeOne built 35-plus assets and 93 trials across 1,100 U.S. sites by September 2026.
  • BRUKINSA dominates revenue, with 2026 global sales above $1.2 billion quarterly.
  • Hopewell, New Jersey gives BeOne U.S. manufacturing, R&D, and packaging capacity.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

Wellness Program

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

6%

1 year growth

-9%

2 year growth

-3%
Yahoo Finance
Sep 4th, 2026
BeOne secures US pharma-tariff exemption after $1B+ manufacturing investment, but pricing concessions raise margin concerns

BeOne Medicines secured an exemption from Section 232 pharmaceutical tariffs through a voluntary agreement with the US government. The deal recognises over $1 billion in US manufacturing investment, including a $300 million expansion in Hopewell, New Jersey. The exemption protects BeOne from import duties on patented pharmaceuticals and ingredients. However, the company committed to pricing future FDA-approved medicines in line with other developed markets and participating in the Medicaid GENEROUS Model, which uses supplemental rebates. The Hopewell expansion will add small-molecule manufacturing and packaging capacity, creating approximately 120 full-time jobs. The facility will support a portfolio of more than 35 assets. Whilst the tariff exemption reduces supply-chain risk, international reference pricing commitments could limit pricing flexibility for future oncology medicines. Neither the tariff savings nor the financial impact of pricing concessions was disclosed.

Yahoo Finance
Aug 13th, 2026
Revolution Medicines shares rise 6.2% on BeOne-funded Phase 3 RAS(ON) deal

Revolution Medicines has partnered with BeOne Medicines in a multi-part collaboration combining BeOne's oncology assets with Revolution's four clinical RAS(ON) inhibitors. The August 2026 deal grants BeOne exclusive development and commercialisation rights in select Asian markets and commits BeOne to fund a global Phase 3 trial. Revolution Medicines reported a net loss of $644.37 million in Q2 2026 and $1.1 billion over six months. The company currently generates no revenue but projects $2.3 billion in revenue and $402.5 million in earnings by 2029. The partnership shifts near-term risk by offloading Phase 3 costs whilst providing access to milestone and royalty potential. However, the core investment case remains unchanged: regulatory progress and commercialisation of daraxonrasib, with trial execution and spending presenting the biggest risks.

Yahoo Finance
Aug 5th, 2026
BeOne Medicines Q2 revenue up 30% to $1.7B as BRUKINSA sales top $1.2B globally

BeOne Medicines reported second-quarter revenue of $1.7 billion, up 30% year over year, with GAAP earnings per ADS rising 144% to $2.05. The company's BTK inhibitor BRUKINSA generated more than $1.2 billion in global sales, increasing 31% from the prior year. The company raised its 2026 revenue guidance to CNY 6.6 billion–CNY 6.8 billion and expects GAAP operating income of CNY 1 billion–CNY 1.1 billion. Free cash flow doubled year over year to CNY 435 million. BeOne received FDA approval for Beqalzi in relapsed or refractory mantle cell lymphoma and reported positive Phase III results for a chemotherapy-free BRUKINSA regimen. US BRUKINSA sales totalled $893 million, up 31%, driven by demand in chronic lymphocytic leukaemia and non-CLL indications.

Yahoo Finance
Jul 23rd, 2026
BeOne CEO sells $34.6M in stock while retaining 50M+ shares

John Oyler, chief executive officer of BeOne Medicines AG, sold 109,713 American Depositary Shares worth $34.6 million on 20 and 21 July 2026, according to SEC filings. The transactions were executed under a Rule 10b5-1 trading plan adopted in March 2026. Despite the sale, Oyler retains a substantial ownership position exceeding 50.4 million total shares through various holdings. These include 28.2 million shares held through Oyler Investment LLC and 9.5 million shares in a Roth IRA account. The shares were sold at a weighted average price of $315.28. BeOne Medicines is a commercial-stage oncology biopharmaceutical company with $5.7 billion in trailing twelve-month revenue and a market capitalisation of $34.2 billion.

PR Newswire
Jul 21st, 2026
Seegene USA receives FDA emergency authorisation for first multiplex PCR test to diagnose viral causes of ulcerative skin lesions

Seegene USA has received Emergency Use Authorization from the FDA for its Allplex HSV-1&2/VZV/MPXV Assay, a multiplex real-time PCR test that simultaneously detects herpes simplex virus types 1 and 2, varicella-zoster virus, and monkeypox virus. It is the first multiplex PCR test designed to support differential diagnosis of viral causes of ulcerative skin lesions in the US market. These pathogens often present with similar clinical symptoms that are difficult to distinguish visually. Research presented at the 2024 Clinical Virology Symposium found that a multiplex PCR assay identified HSV, VZV, or MPXV in 54 out of 966 samples that had previously tested negative using single-pathogen methods. The assay was developed using Seegene's proprietary multiplex PCR technologies and automated product development platform.